Complement Inhibitors Market: Distribution by Target Disease Indication (Atypical Hemolytic Uremic Syndrome, Cardiac Transplantation Rejection, Cold Agglutinin Disease, COVID-19, Generalized Myasthenia Gravis, Guillain-Barre Syndrome, Hereditary Angioedema, Neuromyelitis Optica and Paroxysmal Nocturnal Hemoglobinuria), Therapeutic Area (Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological and Neuromuscular Disorders), Type of Molecule (Biologic and Small Molecule), Target Pathway (Alternate, Classical, Lectin and Terminal Pathway), Type of Therapy (Monotherapy and Combination Therapy), Route of Administration (Intravenous, Oral and Subcutaneous), Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2022-2035
The projected value of complement inhibitors market is expected to be valued at USD 6,800 million in 2022 and is anticipated to grow at a CAGR of 15% during the forecast period 2022-2035.
Since the approval of Soliris® in 2007, the landscape of complement drug discovery has garnered substantial attention within the medical and pharmaceutical communities. Presently, there are nine commercially available complement therapeutics, with an impressive pipeline of approximately 190 molecules in various stages of development across diverse disease indications. Noteworthy among these are Berinert®, Cinryze®, ORLADEYO®, Ruconest®, and TAKHZYRO®, all having received approval from both the US FDA and the EMA for the treatment of hereditary angioedema. In a groundbreaking development, the FDA has granted approval for EMPAVELITM (pegcetacoplan), a pioneering complement C3 inhibitor developed by Apellis Pharmaceuticals, specifically for paroxysmal nocturnal hemoglobinuria. This marks a significant stride forward, presenting potential applications in autoimmune and inflammatory disorders, and emphasizes the expanding scope of complement-targeted therapeutic interventions.
The complement system, elucidated in the 19th century, stands as a pivotal component of the innate immune system and tissue homeostasis. Its role in regulating cell survival and pathogen elimination is crucial. Dysregulation in complement activation can lead to various diseases, catalyzing the development of complement-targeted therapeutics aimed at inhibiting activation, thereby mitigating tissue inflammation and modulating the adaptive immune response. The ongoing research in this arena is concentrating on the next generation of complement therapeutics, encompassing biologics, gene therapies, oligonucleotides, small interfering RNAs, and small molecule-based options, each tailored to address specific disease conditions.
As a multifaceted innate immune surveillance system, the complement system presents a rich field for uncovering novel therapeutic targets in the future. Research endeavors in this domain, bolstered by grants totaling USD 837 million from the National Institutes of Health, are propelling advancements. The active participation of both established pharmaceutical companies and new entrants underscores the dynamism of the complement therapeutics market, positioning it for consistent growth. The optimism in the field is further fueled by encouraging clinical research, a broadened disease focus, and innovative approaches extending beyond C5. These efforts not only aim to decrease costs but also address safety concerns, thereby molding the complement therapeutics landscape in the years ahead. The future holds promise for a comprehensive transformation in the understanding and treatment of diseases through the continued evolution of complement-targeted therapies.
Research Coverage
Since the approval of Soliris® in 2007, the landscape of complement drug discovery has garnered substantial attention within the medical and pharmaceutical communities. Presently, there are nine commercially available complement therapeutics, with an impressive pipeline of approximately 190 molecules in various stages of development across diverse disease indications. Noteworthy among these are Berinert®, Cinryze®, ORLADEYO®, Ruconest®, and TAKHZYRO®, all having received approval from both the US FDA and the EMA for the treatment of hereditary angioedema. In a groundbreaking development, the FDA has granted approval for EMPAVELITM (pegcetacoplan), a pioneering complement C3 inhibitor developed by Apellis Pharmaceuticals, specifically for paroxysmal nocturnal hemoglobinuria. This marks a significant stride forward, presenting potential applications in autoimmune and inflammatory disorders, and emphasizes the expanding scope of complement-targeted therapeutic interventions.
The complement system, elucidated in the 19th century, stands as a pivotal component of the innate immune system and tissue homeostasis. Its role in regulating cell survival and pathogen elimination is crucial. Dysregulation in complement activation can lead to various diseases, catalyzing the development of complement-targeted therapeutics aimed at inhibiting activation, thereby mitigating tissue inflammation and modulating the adaptive immune response. The ongoing research in this arena is concentrating on the next generation of complement therapeutics, encompassing biologics, gene therapies, oligonucleotides, small interfering RNAs, and small molecule-based options, each tailored to address specific disease conditions.
As a multifaceted innate immune surveillance system, the complement system presents a rich field for uncovering novel therapeutic targets in the future. Research endeavors in this domain, bolstered by grants totaling USD 837 million from the National Institutes of Health, are propelling advancements. The active participation of both established pharmaceutical companies and new entrants underscores the dynamism of the complement therapeutics market, positioning it for consistent growth. The optimism in the field is further fueled by encouraging clinical research, a broadened disease focus, and innovative approaches extending beyond C5. These efforts not only aim to decrease costs but also address safety concerns, thereby molding the complement therapeutics landscape in the years ahead. The future holds promise for a comprehensive transformation in the understanding and treatment of diseases through the continued evolution of complement-targeted therapies.
Research Coverage
- A comprehensive overview of the complement system, detailing immune cells, key proteins, activation pathways, consequences of dysregulation, types of complement therapeutics, limitations, and the future landscape.
- An analysis of the current market landscape for next generation complement therapeutics, considering parameters like development status, molecule type, biological target, pathway, mechanism of action, disease indication, therapeutic area, administration route, and therapy type.
- A detailed profiles of major players in next generation complement therapeutics development, featuring company overviews, financial information, product portfolios, recent developments, and future outlooks.
- Over 870 clinical studies of next generation complement therapeutics, covering trial status, registration year, phase, patient population, sponsor type, study type, design, industry/non-industry players, indications, drug types, focus areas, and regional distribution.
- Over 1,450 scientific articles on next generation complement therapeutics, exploring publication years, focus areas, top authors, research journals, indications, and therapeutic areas.
- Grants awarded for next generation complement therapeutics research from 2017-2021, considering parameters like year, amount, funding institute, support period, grant type, activity code, recipient organizations, NIH departments, study sections, focus areas, program officers, and locations.
- An in-depth analysis of patents filed/granted for next generation complement therapeutics between 2016-2021, covering publication year, patent type, location, CPC symbols, applicant type, patent age, focus areas, leading players, characteristics, benchmarking, and valuation.
- Detailed partnerships in the domain, encompassing clinical trials, distribution, licensing, product development, manufacturing agreements, research, and development agreements, and other relevant deals.
- List of funding and investments since 2014, including venture capital financing, secondary offerings, private placements, grants, debt financing, and other equity in companies focusing on next generation complement therapeutics.
- Detailed analysis of big pharma players in the field, using spider web, Harvey ball, and wind rose chart analyses based on parameters like therapeutics under development, molecule type, development status, therapeutic areas, partnerships, patents, and years of experience.
- A detailed market forecast analysis, projecting the future potential of the next generation complement therapeutics market until 2035. It includes sales projections segmented by target disease indications, therapeutic areas, molecule type, target pathway, therapy type, administration route, and geographical regions.
- Amgen
- CSL Behring
- Innovent Biologics
- Novartis
- Regeneron
- Roche
- Sanofi
- Takeda
- UCB
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Complement System
3.2. Immune Cells Involved in Complement System
3.3. Characteristics of Complement System
3.4. Functions of Complement System
3.5. Role of Complement in Homeostasis and Stress Conditions
3.6. Activation of Complement System
3.6.1. Steps in Complement Activation
3.7. Sources of Key Complement Proteins
3.8. Functions of Complement Proteins of Classical Pathway
3.9. Pathways of Complement System
3.9.1. Classical Pathway
3.9.2. Lectin Pathway
3.9.3. Alternative Pathway
3.9.4. Terminal Pathway
3.10. Consequences of a Dysregulated Complement System
3.11. Diseases related to Defects in Complement Proteins
3.12. Types of Complement Therapeutics
3.13. Limitations of Complement Therapeutics
3.14. Future of Next Generation Complement Therapeutics
4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Next Generation Complement Therapeutics: Development Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Status of Development and Type of Molecule
4.2.4. Analysis by Type of Drug
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Target Pathway
4.2.7. Analysis by Mechanism of Action
4.2.8. Analysis by Mechanism of Action and Target Pathway
4.2.9. Analysis by Target Disease Indication(s)
4.2.10. Analysis by Status of Development and Target Disease Indication(s)
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Therapeutic Area and Type of Molecule
4.2.13. Analysis by Route of Administration
4.2.14. Analysis by Type of Therapy
4.2.15. Analysis by Dosing Frequency
4.2.16. Grid Analysis: Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
4.3. Next Generation Complement Therapeutics: List of Drugs with Special Designations
4.3.1. Analysis by Special Designation
4.4. Next Generation Complement Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Region of Headquarters
4.4.4. Analysis by Company Size and Region of Headquarters
4.4.5. Leading Players: Analysis by Number of Therapeutics
5. COMPANY PROFILES
5.1. Amgen
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. CSL Behring
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Innovent Biologics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Novartis
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Regeneron
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Roche
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Sanofi
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Takeda
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. UCB
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Complement Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Cumulative Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Type of Study
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Disease Indication
6.2.13. Most Popular Therapeutic Areas: Analysis by Number of Trials
6.2.14. Analysis by Type of Treatment
6.2.15. Analysis by Type of Drug
6.2.16. Word Cloud Analysis: Emerging Focus Areas
6.2.17. Analysis by Top Indications and Phase of the Trial
6.2.18. Analysis by Top Indications and Leading Industry Players
6.2.19. Analysis by Trial Location
6.2.20. Analysis by Geography and Trial Status
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Next Generation Complement Therapeutics: List of Publications
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Top Authors: Analysis by Number of Publications
7.2.4. Key Journals based on Number of Publications
7.2.5. Key Journals based on Impact Factor
7.2.6. Popular Indications based on Number of Publications
7.2.7. Popular Therapeutic Areas based on Number of Publications
8. GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.1.1. Analysis by Year of Grants Awarded
8.1.2. Analysis by Amount Awarded
8.1.3. Analysis by Funding Institute Center
8.1.4. Analysis by Support Period
8.1.5. Analysis by Funding Institute Center and Support Period
8.1.6. Analysis by Type of Grant
8.1.7. Analysis by Activity Code
8.1.8. Popular Recipient Organizations: Analysis by Number of Grants
8.1.9. Popular Recipient Organizations: Analysis by Amount Awarded
8.1.10. Popular NIH Departments: Analysis by Number of Grants
8.1.11. Analysis by Study Section
8.1.12. Analysis by Type of Recipient Organization
8.1.13. Word Cloud Analysis: Emerging Focus Areas
8.1.14. Analysis by Purpose of Grant
8.1.15. Prominent Program Officers: Analysis by Number of Grants
8.1.16. Analysis by Location of Recipient Organizations
9. PATENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Complement Therapeutics: List of Patents
9.2.1. Analysis by Patent Publication Year
9.2.2. Analysis of Year-wise Granted Patents
9.2.3. Analysis by Type of Patent
9.2.4. Analysis by Granted Patents and Patent Applications
9.2.5. Analysis by Geography
9.2.6. Analysis by CPC Symbols
9.2.7. Analysis by Type of Applicant
9.2.8. Analysis of Patents by Age
9.2.9. Word Cloud Analysis: Emerging Focus Areas
9.2.10. Leading Industry Players: Analysis by Number of Patents
9.2.11. Leading Non-Industry Players: Analysis by Number of Patents
9.2.12. Leading Individual Assignees: Analysis by Number of Patents
9.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
9.2.14. Patent Valuation: Analysis Methodology and Parameters
9.2.15. Patent Valuation: Analysis by Relative Valuation
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Next Generation Complement Therapeutics: List of Partnerships and Collaborations
10.1.1. Analysis by Year-wise Trend of Partnership
10.1.2. Analysis by Type of Partnership
10.1.3. Analysis by Year and Type of Partnership
10.1.4. Most Popular Drug: Analysis by Number of Partnerships
10.1.5. Analysis by Biological Target
10.1.6. Analysis by Target Pathway
10.1.7. Word Cloud Analysis: Emerging Focus Areas
10.1.8. Analysis by Drug and Type of Partnership
10.1.9. Analysis by Type of Partner
10.1.10. Analysis by Popular Disease Indication
10.1.11. Analysis by Popular Disease Indication and Type of Partnership
10.1.12. Analysis by Therapeutic Area
10.1.13. Analysis by Therapeutic Area and Type of Partnership
10.1.14. Regional Analysis of Partnerships
10.1.15. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Next Generation Complement Therapeutics: List of Funding and Investments
11.1.1. Cumulative Year-wise Trend
11.1.2. Analysis by Amount Invested per Year
11.1.3. Analysis by Type of Funding and Year of Establishment
11.1.4. Analysis of Instances by Type of Funding
11.1.5. Analysis of Amount Invested by Type of Funding
11.1.6. Analysis by Year, Type of Funding and Amount Invested
11.1.7. Most Active Investors: Analysis by Number of Instances
11.1.8. Most Active Players: Analysis by Number of Funding Instances
11.1.9. Most Active Players: Analysis by Amount Raised
11.1.10. Analysis of Amount by Drug
11.1.11. Analysis of Number of Instances by Drug
11.1.12. Summary of Investments
12. BIG PHARMA PLAYERS
12.1 Analysis Methodology and Key Parameters
12.2. Scoring of Parameters
12.3. Big Pharma Players: Information on Revenues Generated in 2021
12.3.1. Analysis by Supplier Strength
12.3.2. Analysis by Portfolio Strength
12.3.3. Analysis by Portfolio Diversity
12.3.4. Benchmarking: Spider Web Analysis
12.3.5. Benchmarking: Harvey Ball Analysis
12.3.6. Benchmarking: Wind Rose Chart
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Parameters
13.2. Global Next Generation Complement Therapeutics Market, 2022-2035
13.3. Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035
13.3.1. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Disease Indication
13.3.1.1. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
13.3.1.2. Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035
13.3.2. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Molecule
13.3.2.1. Next Generation Complement Therapeutics Market for Biologics, 2022-2035
13.3.2.2. Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035
13.3.3. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Pathway
13.3.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.3.3.2. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
13.3.3.3. Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035
13.3.3.4. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
13.3.4. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Therapy
13.3.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.3.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
13.3.5. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Route of Administration
13.3.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.3.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
13.3.5.3. Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035
13.4. Product-wise Sales Forecast for Marketed Drugs
13.4.1. Berinert (CSL Behring)
13.4.1.1. Sales Forecast (USD Billion)
13.4.2. EMPAVELI (Apellis Pharmaceuticals)
13.4.2.1. Sales Forecast (USD Billion)
13.4.3. ORLADEYO (BioCryst Pharmaceuticals)
13.4.3.1. Sales Forecast (USD Billion)
13.4.4. Ruconest (Pharming)
13.4.4.1. Sales Forecast (USD Billion)
13.4.5. Soliris (Alexion Pharmaceuticals)
13.4.5.1. Sales Forecast (USD Billion)
13.4.6. Takhzyro (Takeda)
13.4.6.1. Sales Forecast (USD Billion)
13.4.7. Ultomiris (Alexion Pharmaceuticals)
13.4.7.1. Sales Forecast (USD Billion)
13.5. Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035
13.5.1. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Disease Indication
13.5.1.1. Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
13.5.1.2. Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035
13.5.1.3. Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035
13.5.1.4. Next Generation Complement Therapeutics Market for COVID-19, 2022-2035
13.5.1.5. Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035
13.5.1.6. Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035
13.5.1.7. Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035
13.5.1.8. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
13.5.2. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Therapeutic Area
13.5.2.1. Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035
13.5.2.2. Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035
13.5.2.3. Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035
13.5.2.4. Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035
13.5.2.5. Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035
13.5.2.6. Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035
13.5.3. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Pathway
13.5.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.5.3.2. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
13.5.3.3. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
13.5.4. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Type of Therapy
13.5.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.5.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
13.5.5. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Route of Administration
13.5.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.5.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
13.5.6. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Geography
13.5.6.1. Next Generation Complement Therapeutics Market in North America, 2022-2035
13.5.6.1.1. Next Generation Complement Therapeutics Market in US, 2022-2035
13.5.6.1.2. Next Generation Complement Therapeutics Market in Canada, 2022-2035
13.5.6.2. Next Generation Complement Therapeutics Market in Europe, 2022-2035
13.5.6.2.1. Next Generation Complement Therapeutics Market in UK, 2022-2035
13.5.6.2.2. Next Generation Complement Therapeutics Market in Germany, 2022-2035
13.5.6.2.3. Next Generation Complement Therapeutics Market in France, 2022-2035
13.5.6.2.4. Next Generation Complement Therapeutics Market in Italy, 2022-2035
13.5.6.2.5. Next Generation Complement Therapeutics Market in Spain, 2022-2035
13.5.6.3. Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035
13.5.6.3.1. Next Generation Complement Therapeutics Market in Australia, 2022-2035
13.5.6.3.2. Next Generation Complement Therapeutics Market in Japan, 2022-2035
13.5.6.3.3. Next Generation Complement Therapeutics Market in China, 2022-2035
13.5.6.3.4. Next Generation Complement Therapeutics Market in India, 2022-2035
13.6. Product-wise Sales Forecast for Phase III Drugs
13.6.1. Narsoplimab (Omeros)
13.6.1.1. Target Patient Population
13.6.1.2. Sales Forecast (USD Billion)
13.6.1.3. Net Present Value (USD Billion)
13.6.1.4. Value Creation Analysis
13.6.2. REGN3918 (Regeneron)
13.6.2.1. Target Patient Population
13.6.2.2. Sales Forecast (USD Billion)
13.6.2.3. Net Present Value (USD Billion)
13.6.2.4. Value Creation Analysis
13.6.3. RG6107 (Ruconest)
13.6.3.1. Target Patient Population
13.6.3.2. Sales Forecast (USD Billion)
13.6.3.3. Net Present Value (USD Billion)
13.6.3.4. Value Creation Analysis
13.6.4. rVA576 (Akari Therapeutics)
13.6.4.1. Target Patient Population
13.6.4.2. Sales Forecast (USD Billion)
13.6.4.3. Net Present Value (USD Billion)
13.6.4.4. Value Creation Analysis
13.6.5. SAR445088 (Sanofi)
13.6.5.1. Target Patient Population
13.6.5.2. Sales Forecast (USD Billion)
13.6.5.3. Net Present Value (USD Billion)
13.6.5.4. Value Creation Analysis
13.6.6. Soliris (Alexion Pharmaceuticals)
13.6.6.1. Target Patient Population
13.6.6.2. Sales Forecast (USD Billion)
13.6.6.3. Net Present Value (USD Billion)
13.6.6.4. Value Creation Analysis
13.6.7. Sutimlimab (Bioverativ)
13.6.7.1. Target Patient Population
13.6.7.2. Sales Forecast (USD Billion)
13.6.7.3. Net Present Value (USD Billion)
13.6.7.4. Value Creation Analysis
13.6.8. Vilobelimab (InflaRx)
13.6.8.1. Target Patient Population
13.6.8.2. Sales Forecast (USD Billion)
13.6.8.3. Net Present Value (USD Billion)
13.6.8.4. Value Creation Analysis
13.6.9. Zilucoplan (UCB)
13.6.9.1. Target Patient Population
13.6.9.2. Sales Forecast (USD Billion)
13.6.9.3. Net Present Value (USD Billion)
13.6.9.4. Value Creation Analysis
13.7. Summary: Phase III Drugs
14. EXPERT OPINION
14.1. New York Oncology Hematology
14.1.1. Overview of Organization
14.1.2. Expert Opinion: Mihir Raval (Physician)
14.2. Cedars-Sinai Tower Hematology Oncology Medical
14.2.1. Overview of Organization
14.2.2. Expert Opinion: Jeremy Lorber (Hematologist Oncologist)
14.3. Weill Cornell Medical College
14.3.1. Overview of Organization
14.3.2. Expert Opinion: Jeffrey Conrad Laurence (Senior Scientific Consultant)
14.4. Leiden University Medical Center
14.4.1. Overview of Organization
14.4.2. Expert Opinion: YKO (Onno) Teng (Nephrology Clinician-Scientist
14.5. Lund University
14.5.1. Overview of Organization
14.5.2. Expert Opinion: M?rten Segelmark (Professor of Nephrology)
15. APPENDIX 1: LIST OF FIGURES AND TABLES
16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Overview of Complement System
3.2. Immune Cells Involved in Complement System
3.3. Characteristics of Complement System
3.4. Functions of Complement System
3.5. Role of Complement in Homeostasis and Stress Conditions
3.6. Activation of Complement System
3.6.1. Steps in Complement Activation
3.7. Sources of Key Complement Proteins
3.8. Functions of Complement Proteins of Classical Pathway
3.9. Pathways of Complement System
3.9.1. Classical Pathway
3.9.2. Lectin Pathway
3.9.3. Alternative Pathway
3.9.4. Terminal Pathway
3.10. Consequences of a Dysregulated Complement System
3.11. Diseases related to Defects in Complement Proteins
3.12. Types of Complement Therapeutics
3.13. Limitations of Complement Therapeutics
3.14. Future of Next Generation Complement Therapeutics
4. NEXT GENERATION COMPLEMENT THERAPEUTICS: MARKET LANDSCAPE
4.1. Analysis Methodology and Key Parameters
4.2. Next Generation Complement Therapeutics: Development Pipeline
4.2.1. Analysis by Status of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Status of Development and Type of Molecule
4.2.4. Analysis by Type of Drug
4.2.5. Analysis by Biological Target
4.2.6. Analysis by Target Pathway
4.2.7. Analysis by Mechanism of Action
4.2.8. Analysis by Mechanism of Action and Target Pathway
4.2.9. Analysis by Target Disease Indication(s)
4.2.10. Analysis by Status of Development and Target Disease Indication(s)
4.2.11. Analysis by Therapeutic Area
4.2.12. Analysis by Therapeutic Area and Type of Molecule
4.2.13. Analysis by Route of Administration
4.2.14. Analysis by Type of Therapy
4.2.15. Analysis by Dosing Frequency
4.2.16. Grid Analysis: Type of Therapy, Type of Molecule, Route of Administration and Mechanism of Action
4.3. Next Generation Complement Therapeutics: List of Drugs with Special Designations
4.3.1. Analysis by Special Designation
4.4. Next Generation Complement Therapeutics: Developer Landscape
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Region of Headquarters
4.4.4. Analysis by Company Size and Region of Headquarters
4.4.5. Leading Players: Analysis by Number of Therapeutics
5. COMPANY PROFILES
5.1. Amgen
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. CSL Behring
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Innovent Biologics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Novartis
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Regeneron
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Roche
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Sanofi
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Takeda
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. UCB
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Analysis Methodology and Key Parameters
6.2. Next Generation Complement Therapeutics: List of Clinical Trials
6.2.1. Analysis by Trial Status
6.2.2. Cumulative Analysis by Trial Registration Year
6.2.3. Analysis by Trial Registration Year and Status
6.2.4. Analysis by Trial Phase
6.2.5. Analysis by Trial Phase and Patients Enrolled
6.2.6. Analysis by Trial Registration Year and Patients Enrolled
6.2.7. Analysis by Type of Sponsor / Collaborator
6.2.8. Analysis by Type of Study
6.2.9. Analysis by Study Design
6.2.10. Most Active Industry Players: Analysis by Number of Trials
6.2.11. Most Active Non-Industry Players: Analysis by Number of Trials
6.2.12. Analysis by Disease Indication
6.2.13. Most Popular Therapeutic Areas: Analysis by Number of Trials
6.2.14. Analysis by Type of Treatment
6.2.15. Analysis by Type of Drug
6.2.16. Word Cloud Analysis: Emerging Focus Areas
6.2.17. Analysis by Top Indications and Phase of the Trial
6.2.18. Analysis by Top Indications and Leading Industry Players
6.2.19. Analysis by Trial Location
6.2.20. Analysis by Geography and Trial Status
7. PUBLICATION ANALYSIS
7.1. Analysis Methodology and Key Parameters
7.2. Next Generation Complement Therapeutics: List of Publications
7.2.1. Analysis by Year of Publication
7.2.2. Word Cloud Analysis: Emerging Focus Areas
7.2.3. Top Authors: Analysis by Number of Publications
7.2.4. Key Journals based on Number of Publications
7.2.5. Key Journals based on Impact Factor
7.2.6. Popular Indications based on Number of Publications
7.2.7. Popular Therapeutic Areas based on Number of Publications
8. GRANT ANALYSIS
8.1. Analysis Methodology and Key Parameters
8.1.1. Analysis by Year of Grants Awarded
8.1.2. Analysis by Amount Awarded
8.1.3. Analysis by Funding Institute Center
8.1.4. Analysis by Support Period
8.1.5. Analysis by Funding Institute Center and Support Period
8.1.6. Analysis by Type of Grant
8.1.7. Analysis by Activity Code
8.1.8. Popular Recipient Organizations: Analysis by Number of Grants
8.1.9. Popular Recipient Organizations: Analysis by Amount Awarded
8.1.10. Popular NIH Departments: Analysis by Number of Grants
8.1.11. Analysis by Study Section
8.1.12. Analysis by Type of Recipient Organization
8.1.13. Word Cloud Analysis: Emerging Focus Areas
8.1.14. Analysis by Purpose of Grant
8.1.15. Prominent Program Officers: Analysis by Number of Grants
8.1.16. Analysis by Location of Recipient Organizations
9. PATENT ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. Next Generation Complement Therapeutics: List of Patents
9.2.1. Analysis by Patent Publication Year
9.2.2. Analysis of Year-wise Granted Patents
9.2.3. Analysis by Type of Patent
9.2.4. Analysis by Granted Patents and Patent Applications
9.2.5. Analysis by Geography
9.2.6. Analysis by CPC Symbols
9.2.7. Analysis by Type of Applicant
9.2.8. Analysis of Patents by Age
9.2.9. Word Cloud Analysis: Emerging Focus Areas
9.2.10. Leading Industry Players: Analysis by Number of Patents
9.2.11. Leading Non-Industry Players: Analysis by Number of Patents
9.2.12. Leading Individual Assignees: Analysis by Number of Patents
9.2.13. Leading Players: Benchmarking by Patent Characteristics (CPC Symbols)
9.2.14. Patent Valuation: Analysis Methodology and Parameters
9.2.15. Patent Valuation: Analysis by Relative Valuation
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Next Generation Complement Therapeutics: List of Partnerships and Collaborations
10.1.1. Analysis by Year-wise Trend of Partnership
10.1.2. Analysis by Type of Partnership
10.1.3. Analysis by Year and Type of Partnership
10.1.4. Most Popular Drug: Analysis by Number of Partnerships
10.1.5. Analysis by Biological Target
10.1.6. Analysis by Target Pathway
10.1.7. Word Cloud Analysis: Emerging Focus Areas
10.1.8. Analysis by Drug and Type of Partnership
10.1.9. Analysis by Type of Partner
10.1.10. Analysis by Popular Disease Indication
10.1.11. Analysis by Popular Disease Indication and Type of Partnership
10.1.12. Analysis by Therapeutic Area
10.1.13. Analysis by Therapeutic Area and Type of Partnership
10.1.14. Regional Analysis of Partnerships
10.1.15. Intercontinental and Intracontinental Agreements
11. FUNDING AND INVESTMENT ANALYSIS
11.1. Next Generation Complement Therapeutics: List of Funding and Investments
11.1.1. Cumulative Year-wise Trend
11.1.2. Analysis by Amount Invested per Year
11.1.3. Analysis by Type of Funding and Year of Establishment
11.1.4. Analysis of Instances by Type of Funding
11.1.5. Analysis of Amount Invested by Type of Funding
11.1.6. Analysis by Year, Type of Funding and Amount Invested
11.1.7. Most Active Investors: Analysis by Number of Instances
11.1.8. Most Active Players: Analysis by Number of Funding Instances
11.1.9. Most Active Players: Analysis by Amount Raised
11.1.10. Analysis of Amount by Drug
11.1.11. Analysis of Number of Instances by Drug
11.1.12. Summary of Investments
12. BIG PHARMA PLAYERS
12.1 Analysis Methodology and Key Parameters
12.2. Scoring of Parameters
12.3. Big Pharma Players: Information on Revenues Generated in 2021
12.3.1. Analysis by Supplier Strength
12.3.2. Analysis by Portfolio Strength
12.3.3. Analysis by Portfolio Diversity
12.3.4. Benchmarking: Spider Web Analysis
12.3.5. Benchmarking: Harvey Ball Analysis
12.3.6. Benchmarking: Wind Rose Chart
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Forecast Methodology and Key Parameters
13.2. Global Next Generation Complement Therapeutics Market, 2022-2035
13.3. Global Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035
13.3.1. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Disease Indication
13.3.1.1. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
13.3.1.2. Next Generation Complement Therapeutics Market for Hereditary Angioedema, 2022-2035
13.3.2. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Molecule
13.3.2.1. Next Generation Complement Therapeutics Market for Biologics, 2022-2035
13.3.2.2. Next Generation Complement Therapeutics Market for Small Molecules, 2022-2035
13.3.3. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Target Pathway
13.3.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.3.3.2. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
13.3.3.3. Next Generation Complement Therapeutics Market for Alternate Pathway, 2022-2035
13.3.3.4. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
13.3.4. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Type of Therapy
13.3.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.3.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
13.3.5. Next Generation Complement Therapeutics Market for Marketed Drugs, 2022-2035: Distribution by Route of Administration
13.3.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.3.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
13.3.5.3. Next Generation Complement Therapeutics Market for Oral Drugs, 2022-2035
13.4. Product-wise Sales Forecast for Marketed Drugs
13.4.1. Berinert (CSL Behring)
13.4.1.1. Sales Forecast (USD Billion)
13.4.2. EMPAVELI (Apellis Pharmaceuticals)
13.4.2.1. Sales Forecast (USD Billion)
13.4.3. ORLADEYO (BioCryst Pharmaceuticals)
13.4.3.1. Sales Forecast (USD Billion)
13.4.4. Ruconest (Pharming)
13.4.4.1. Sales Forecast (USD Billion)
13.4.5. Soliris (Alexion Pharmaceuticals)
13.4.5.1. Sales Forecast (USD Billion)
13.4.6. Takhzyro (Takeda)
13.4.6.1. Sales Forecast (USD Billion)
13.4.7. Ultomiris (Alexion Pharmaceuticals)
13.4.7.1. Sales Forecast (USD Billion)
13.5. Global Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035
13.5.1. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Disease Indication
13.5.1.1. Next Generation Complement Therapeutics Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
13.5.1.2. Next Generation Complement Therapeutics Market for Cardiac Transplantation Rejection, 2022-2035
13.5.1.3. Next Generation Complement Therapeutics Market for Cold Agglutinin Disease, 2022-2035
13.5.1.4. Next Generation Complement Therapeutics Market for COVID-19, 2022-2035
13.5.1.5. Next Generation Complement Therapeutics Market for Guillain-Barre Syndrome, 2022-2035
13.5.1.6. Next Generation Complement Therapeutics Market for Generalized Myasthenia Gravis, 2022-2035
13.5.1.7. Next Generation Complement Therapeutics Market for Neuromyelitis Optica, 2022-2035
13.5.1.8. Next Generation Complement Therapeutics Market for Paroxysmal Nocturnal Hemoglobinuria, 2022-2035
13.5.2. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Therapeutic Area
13.5.2.1. Next Generation Complement Therapeutics Market for Cardiovascular Disorders, 2022-2035
13.5.2.2. Next Generation Complement Therapeutics Market for Hematological and Vascular Disorders, 2022-2035
13.5.2.3. Next Generation Complement Therapeutics Market for Infectious Diseases, 2022-2035
13.5.2.4. Next Generation Complement Therapeutics Market for Neurological Disorders, 2022-2035
13.5.2.5. Next Generation Complement Therapeutics Market for Neuromuscular Disorders, 2022-2035
13.5.2.6. Next Generation Complement Therapeutics Market for Genetic Disorders, 2022-2035
13.5.3. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Target Pathway
13.5.3.1. Next Generation Complement Therapeutics Market for Terminal Pathway, 2022-2035
13.5.3.2. Next Generation Complement Therapeutics Market for Lectin Pathway, 2022-2035
13.5.3.3. Next Generation Complement Therapeutics Market for Classical Pathway, 2022-2035
13.5.4. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Type of Therapy
13.5.4.1. Next Generation Complement Therapeutics Market for Monotherapy, 2022-2035
13.5.4.2. Next Generation Complement Therapeutics Market for Combination Therapy, 2022-2035
13.5.5. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Route of Administration
13.5.5.1. Next Generation Complement Therapeutics Market for Intravenous Drugs, 2022-2035
13.5.5.2. Next Generation Complement Therapeutics Market for Subcutaneous Drugs, 2022-2035
13.5.6. Next Generation Complement Therapeutics Market for Phase III Drugs, 2022-2035: Distribution by Geography
13.5.6.1. Next Generation Complement Therapeutics Market in North America, 2022-2035
13.5.6.1.1. Next Generation Complement Therapeutics Market in US, 2022-2035
13.5.6.1.2. Next Generation Complement Therapeutics Market in Canada, 2022-2035
13.5.6.2. Next Generation Complement Therapeutics Market in Europe, 2022-2035
13.5.6.2.1. Next Generation Complement Therapeutics Market in UK, 2022-2035
13.5.6.2.2. Next Generation Complement Therapeutics Market in Germany, 2022-2035
13.5.6.2.3. Next Generation Complement Therapeutics Market in France, 2022-2035
13.5.6.2.4. Next Generation Complement Therapeutics Market in Italy, 2022-2035
13.5.6.2.5. Next Generation Complement Therapeutics Market in Spain, 2022-2035
13.5.6.3. Next Generation Complement Therapeutics Market in Asia Pacific, 2022-2035
13.5.6.3.1. Next Generation Complement Therapeutics Market in Australia, 2022-2035
13.5.6.3.2. Next Generation Complement Therapeutics Market in Japan, 2022-2035
13.5.6.3.3. Next Generation Complement Therapeutics Market in China, 2022-2035
13.5.6.3.4. Next Generation Complement Therapeutics Market in India, 2022-2035
13.6. Product-wise Sales Forecast for Phase III Drugs
13.6.1. Narsoplimab (Omeros)
13.6.1.1. Target Patient Population
13.6.1.2. Sales Forecast (USD Billion)
13.6.1.3. Net Present Value (USD Billion)
13.6.1.4. Value Creation Analysis
13.6.2. REGN3918 (Regeneron)
13.6.2.1. Target Patient Population
13.6.2.2. Sales Forecast (USD Billion)
13.6.2.3. Net Present Value (USD Billion)
13.6.2.4. Value Creation Analysis
13.6.3. RG6107 (Ruconest)
13.6.3.1. Target Patient Population
13.6.3.2. Sales Forecast (USD Billion)
13.6.3.3. Net Present Value (USD Billion)
13.6.3.4. Value Creation Analysis
13.6.4. rVA576 (Akari Therapeutics)
13.6.4.1. Target Patient Population
13.6.4.2. Sales Forecast (USD Billion)
13.6.4.3. Net Present Value (USD Billion)
13.6.4.4. Value Creation Analysis
13.6.5. SAR445088 (Sanofi)
13.6.5.1. Target Patient Population
13.6.5.2. Sales Forecast (USD Billion)
13.6.5.3. Net Present Value (USD Billion)
13.6.5.4. Value Creation Analysis
13.6.6. Soliris (Alexion Pharmaceuticals)
13.6.6.1. Target Patient Population
13.6.6.2. Sales Forecast (USD Billion)
13.6.6.3. Net Present Value (USD Billion)
13.6.6.4. Value Creation Analysis
13.6.7. Sutimlimab (Bioverativ)
13.6.7.1. Target Patient Population
13.6.7.2. Sales Forecast (USD Billion)
13.6.7.3. Net Present Value (USD Billion)
13.6.7.4. Value Creation Analysis
13.6.8. Vilobelimab (InflaRx)
13.6.8.1. Target Patient Population
13.6.8.2. Sales Forecast (USD Billion)
13.6.8.3. Net Present Value (USD Billion)
13.6.8.4. Value Creation Analysis
13.6.9. Zilucoplan (UCB)
13.6.9.1. Target Patient Population
13.6.9.2. Sales Forecast (USD Billion)
13.6.9.3. Net Present Value (USD Billion)
13.6.9.4. Value Creation Analysis
13.7. Summary: Phase III Drugs
14. EXPERT OPINION
14.1. New York Oncology Hematology
14.1.1. Overview of Organization
14.1.2. Expert Opinion: Mihir Raval (Physician)
14.2. Cedars-Sinai Tower Hematology Oncology Medical
14.2.1. Overview of Organization
14.2.2. Expert Opinion: Jeremy Lorber (Hematologist Oncologist)
14.3. Weill Cornell Medical College
14.3.1. Overview of Organization
14.3.2. Expert Opinion: Jeffrey Conrad Laurence (Senior Scientific Consultant)
14.4. Leiden University Medical Center
14.4.1. Overview of Organization
14.4.2. Expert Opinion: YKO (Onno) Teng (Nephrology Clinician-Scientist
14.5. Lund University
14.5.1. Overview of Organization
14.5.2. Expert Opinion: M?rten Segelmark (Professor of Nephrology)
15. APPENDIX 1: LIST OF FIGURES AND TABLES
16. APPNEDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
